November 2014 Meeting Announcement, Delaware Valley Mass Spectrometry Discussion Group
- Topic: "Metabolomics, quantitative LC/MS and LC/MS/MS."
- Speaker: Andrew Patterson, Penn State University
- Date: Monday, November 10, 2014. 6:00 PM
- Time: Social Hour: 6:00 PM.
Talk: 7:00 PM.
Please RSVP to John Masucci JMasucci@its.jnj.com by Thursday November 6.
- Place: Department of Chemistry, Villanova University (Room 101, Mendel Hall)
- Abstract: The anti-oxidant tempol reduces obesity in high-fat diet (HFD)-fed mice, but the mechanism for this effect has remained elusive. A mass spectrometry-based metabolomic investigation revealed that tempol altered levels of suspected gut microbe-generated metabolites, thus providing initial clues that tempol may either change the composition of the gut microbiome and/or alter its metabolic potential. Indeed, metagenomics revealed that tempol altered the gut microbiome by preferentially reducing the genus Lactobacillus and its bile salt hydrolase activity leading to the accumulation of intestinal tauro-beta-muricholic acid (T?MCA), a farnesoid X receptor (FXR) antagonist involved in the regulation of bile acid, lipid and glucose metabolism. Using a combination of next generation RNA sequencing, 1H NMR-, and mass spectrometry-based metabolomics, tempol was found to significantly alter the gut microbiota in terms of its metabolic potential (RNAseq) and metabolism (metabolomics). Current work using genetically-modified and germ free mice to distinguish the host from the microbiome response will be presented.
At the Pennsylvania State University as part of the Center for Molecular Toxicology and Carcinogenesis, the Patterson lab is focused on understanding the host-metabolite-microbiome axis—specifically how the manipulation of gut bacteria through xenobiotic exposure or the use of gnotobiotic mouse models impacts bile acid pools, their metabolism, and how they interact with host nuclear receptors. The lab employs a variety of cutting-edge tools, including 1H NMR- and mass spectrometry-based metabolomics, metagenomics/metatranscriptomics, and conventional and gnotobiotic transgenic mice, to facilitate its study of these pathways and understand their impact on human health and disease.
Please send any comments, corrections, or suggestions to
This page has been accessed
times since 9/15 /96 .
Last Updated 02/19/2014